Hengrui Pharma's SHR-1139 injection has been approved to conduct clinical trials

AASTOCKS
2025.11.23 10:02

Hengrui Pharma (01276.HK) announced that its subsidiary Guangdong Hengrui received a notification from the National Medical Products Administration, approving SHR-1139 injection to conduct clinical trials for pyoderma gangrenosum. So far, the total R&D investment for the HR-1139 injection-related project has reached approximately 100 million RMB

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer